Chiesi Global Rare Diseases Debuts in Endocrinology at ENDO 2024

Chiesi Global Rare Diseases, a division of the Chiesi Group dedicated to innovative therapies for rare diseases, will present three abstracts at the upcoming Endocrine Society’s ENDO 2024 Meeting. This prestigious event will take place from June 1-4, 2024, in Boston, Massachusetts. Interested participants can visit Chiesi's product booth (#526) and medical booth (#428) during the conference.

A significant highlight of Chiesi's participation will be an oral presentation discussing the outcomes from a post hoc analysis of three Phase 3 clinical trials on oral octreotide capsules. This analysis focuses on biochemical responses, symptom control, and safety for patients. The presentation will be delivered by Dr. Maria Fleseriu, a respected expert in medicine and neurological surgery, and will take place on June 3rd at 1:45 PM EST.

In addition to the oral presentation, Chiesi will unveil two late-breaking poster presentations. One poster, entitled "Lipodystrophy Severity Score: Validation Of A Tool To Assess Disease Burden In Lipodystrophy," will be presented by Dr. Rebecca J. Brown, a pediatric endocrinologist with the National Institute of Diabetes. This session is scheduled for June 2nd at 12:00 PM EST.

The second poster, "Real-world Biochemical And Symptoms Outcomes With Oral Octreotide: Management Of Acromegaly (MACRO) Registry Experience," will be presented by Dr. Kevin Yuen, a recognized authority in endocrinology and pituitary disorders. This presentation will also occur on June 2nd at 12:00 PM EST.

Chiesi’s involvement in the ENDO 2024 meeting signals its expanding influence in the endometabolic field, especially with the recent acquisition of a new portfolio of products. Attendees are encouraged to visit Chiesi's booths to learn more about their therapeutic focuses, ongoing development programs, and the latest medical information.

Acromegaly is a condition that often arises due to a benign pituitary gland tumor leading to excessive production of growth hormone. This results in severe health issues such as facial changes, intense headaches, joint pain, and enlargement of body parts, including the hands and feet. It can also lead to serious illnesses like type 2 diabetes, hypertension, respiratory issues, and cardiovascular diseases. In the United States, over 25,000 individuals are affected by acromegaly, with approximately 8,000 undergoing treatment with injectable somatostatin receptor ligands (iSRLs). Many patients experience significant challenges with this treatment, including prolonged pain and suboptimal symptom management.

Lipodystrophy syndromes are rare and potentially life-threatening disorders characterized by abnormal fat accumulation and storage in the body. They are categorized into generalized lipodystrophy, marked by a near-total absence of fat tissue, and partial lipodystrophy, where fat loss is limited to specific body areas such as the limbs or upper body. These syndromes can be inherited or acquired and significantly impact patients' lives.

Chiesi Global Rare Diseases aims to provide innovative treatments and support for individuals with rare diseases. As a segment of the Chiesi Group, it is committed to ensuring equal access to therapies, striving to improve the quality of life for as many patients as possible. The unit works closely with the rare disease community worldwide to give a voice to underserved populations in the healthcare system.

The Chiesi Group is a global biopharmaceutical company focused on respiratory health, rare diseases, and specialty care. It aims to enhance individuals' quality of life while acting responsibly toward society and the environment. Chiesi has adopted the status of a Benefit Corporation in several countries, reinforcing its commitment to creating shared value for society. As a certified B Corp since 2019, Chiesi is part of a global community of businesses committed to high social and environmental standards and aims to achieve Net-Zero greenhouse gas emissions by 2035.

With over 85 years of experience, Chiesi operates in 31 countries and employs more than 6,500 people. The company's research and development efforts are headquartered in Parma, Italy, with additional centers in France, the US, Canada, China, the UK, and Sweden.